What the FDA's Compounding Review Means for BPC-157

In July 2026, the FDA's Pharmacy Compounding Advisory Committee met to review whether BPC-157 and six other peptides should be eligible for legal compounding. Most people following the peptide space have little visibility into what a review like this actually changes, so it is worth breaking down. BPC-157 currently sits on the FDA's Category 2 restricted compounding list, meaning licensed compounding pharmacies cannot legally turn it into a prescription product, even though it is widely available online labeled research use only. This review was not a formality. FDA staff scientists had already gone on record recommending against loosening the rules, citing insufficient evidence on safety and effectiveness. Context matters here too. Back in February 2026, the Department of Health and Human Services moved 14 of the 19 peptides on the Category 2 list further out of reach rather than closer to access. The overall regulatory direction this year has leaned toward tightening, not loosening. None of this changes what is legal to sell online as a research compound today. What it does shape is whether a prescriber will ever be able to legally compound BPC-157 for a patient instead of that patient sourcing it independently. Whatever the committee ultimately decides, it is a clear signal of where peptide access in the US is headed over the next year, and it is worth watching regardless of where you land on the underlying question.